5 results about "Hsv infection" patented technology

This invention belongs to the field of natural and chemical medicine technology, and discloses two types of *Symplocos edulis* (a type of plant) from the genus *Symplocos*. Bag Philippians The resorcinol compounds were isolated from [the organism]. The structures of the resorcinol compounds are shown in formula (I) or formula (II). The resorcinol compounds of this invention exhibit significant inhibitory effects on respiratory syncytial virus (RSV) and herpes simplex virus (HSV) even at low concentrations, and show low cytotoxicity and high selectivity, demonstrating promising applications in antiviral drugs and medications for treating diseases caused by RSV and HSV infections.

This invention relates to an HSV-2 nanoparticle vaccine, its preparation method, and its application. The nanoparticles comprise HSV-2 PreF gB mutant protein and ferritin. After assembly, multiple PreF gB mutant proteins are concentrated and displayed on the surface, forming ferritin-PreF gB nanoparticles. The mutation of PreF gB enhances the stability and effective immunogenicity of the gB protein, and its display on the nanoparticle surface further enhances immunogenicity, effectively stimulating the body's cellular immune mechanism, thus becoming an effective vaccine for preventing HSV infection.

Disclosed herein are compositions comprising (a) a nucleoside modified polyribonucleotide encoding a herpes simplex virus-2 (HSV-2) glycoprotein E (gE) antigen or an immunogenic fragment thereof, (b) a nucleoside modified polyribonucleotide encoding a HSV-2 glycoprotein I (gI) antigen or an immunogenic fragment thereof, or (c) a combination thereof. Further disclosed are methods for treating HSV infection using the compositions.

This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated with same in a subject comprising the step of contacting the subject with a composition comprising a quindoline (or similar) structure having significant anti-HSV activity.

This invention relates to an HSV-1 nanoparticle vaccine, its preparation method, and its application. The nanoparticles comprise HSV-1 PreF gB mutant protein and ferritin. After assembly, multiple PreF gB mutant proteins are concentrated and displayed on the surface, forming ferritin-PreF gB nanoparticles. The mutation of PreF gB enhances the stability and effective immunogenicity of the gB protein, and its display on the nanoparticle surface further enhances immunogenicity, effectively stimulating the body's cellular immune mechanism, thus becoming an effective vaccine for preventing HSV infection.